Spinraza, a rare disease treatment, posted 200 billion won in sales over the past three years after registering health insurance benefits. Although there is not much demand, it has achieved high performance in a short period of time due to the nature of expensive treatments worth nearly 100 million won per bottle.

According to IQVIA, a pharmaceutical research firm, on the 3rd, Biogen's Spinraza sold 17.4 billion won in the first quarter, up 18.3% from the same period last year. Although it is less than 20.2 billion won posted in the first quarter of 2020, it has recorded 10 billion won in quarterly sales for three years since the second quarter of 2019.